155 related articles for article (PubMed ID: 29976638)
1. Leptin Receptor Antagonists' Action on HDAC Expression Eliminating the Negative Effects of Leptin in Ovarian Cancer.
Fiedor E; Zajda K; Gregoraszczuk EL
Cancer Genomics Proteomics; 2018; 15(4):329-336. PubMed ID: 29976638
[TBL] [Abstract][Full Text] [Related]
2. The molecular mechanism of action of superactive human leptin antagonist (SHLA) and quadruple leptin mutein Lan-2 on human ovarian epithelial cell lines.
Fiedor E; Gregoraszczuk EŁ
Cancer Chemother Pharmacol; 2016 Sep; 78(3):611-22. PubMed ID: 27480179
[TBL] [Abstract][Full Text] [Related]
3. Superactive human leptin antagonist (SHLA), triple Lan1 and quadruple Lan2 leptin mutein as a promising treatment for human folliculoma.
Fiedor E; Gregoraszczuk EL
Cancer Chemother Pharmacol; 2017 Oct; 80(4):815-827. PubMed ID: 28861689
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Kwiecińska P; Wróbel A; Taubøll E; Gregoraszczuk EŁ
Toxicol Lett; 2014 Jan; 224(2):225-32. PubMed ID: 24200999
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Khabele D; Son DS; Parl AK; Goldberg GL; Augenlicht LH; Mariadason JM; Rice VM
Cancer Biol Ther; 2007 May; 6(5):795-801. PubMed ID: 17387270
[TBL] [Abstract][Full Text] [Related]
6. C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Barroilhet L; Yang J; Hasselblatt K; Paranal RM; Ng SK; Rauh-Hain JA; Welch WR; Bradner JE; Berkowitz RS; Ng SW
Oncogene; 2013 Aug; 32(33):3896-903. PubMed ID: 22945647
[TBL] [Abstract][Full Text] [Related]
7. Superactive human leptin antagonist reverses leptin-induced excessive progesterone and testosterone secretion in porcine ovarian follicles by blocking leptin receptors.
Gregoraszczuk EL; Rak A
J Physiol Pharmacol; 2015 Feb; 66(1):39-46. PubMed ID: 25716963
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.
Pchejetski D; Alfraidi A; Sacco K; Alshaker H; Muhammad A; Monzon L
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1659-71. PubMed ID: 26560874
[TBL] [Abstract][Full Text] [Related]
9. Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer.
Lee S; Choi S; Lee Y; Chung D; Hong S; Park N
J Obstet Gynaecol Res; 2017 Jan; 43(1):220-227. PubMed ID: 27862665
[TBL] [Abstract][Full Text] [Related]
10. Everolimus exhibits anti-tumorigenic activity in obesity-induced ovarian cancer.
Guo H; Zhong Y; Jackson AL; Clark LH; Kilgore J; Zhang L; Han J; Sheng X; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Apr; 7(15):20338-56. PubMed ID: 26959121
[TBL] [Abstract][Full Text] [Related]
11. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
12. Gonadotropin signalling in epithelial ovarian cancer.
Mertens-Walker I; Baxter RC; Marsh DJ
Cancer Lett; 2012 Nov; 324(2):152-9. PubMed ID: 22634496
[TBL] [Abstract][Full Text] [Related]
13. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
14. Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Lee CS; Kwak SW; Kim YJ; Lee SA; Park ES; Myung SC; Kim W; Lee MS; Lee JJ
Eur J Pharmacol; 2012 May; 683(1-3):54-62. PubMed ID: 22465181
[TBL] [Abstract][Full Text] [Related]
15. [Expression of aFGF in ovarian epithelial cancer and its signal transduction pathway].
Zhang Y; Sun LG; Shang H; Gao H; Yu HY; Gao SM; Liu N
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):976-80. PubMed ID: 12899800
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
Du J; Li B; Fang Y; Liu Y; Wang Y; Li J; Zhou W; Wang X
BMC Cancer; 2015 Jul; 15():536. PubMed ID: 26198101
[TBL] [Abstract][Full Text] [Related]
17. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
18. Bisphenol A induces leptin receptor expression, creating more binding sites for leptin, and activates the JAK/Stat, MAPK/ERK and PI3K/Akt signalling pathways in human ovarian cancer cell.
Ptak A; Gregoraszczuk EL
Toxicol Lett; 2012 May; 210(3):332-7. PubMed ID: 22343039
[TBL] [Abstract][Full Text] [Related]
19. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of differentially expressed proteins in epithelial ovarian cancers using quantitative proteomics.
Qu H; Chen Y; Cao G; Liu C; Xu J; Deng H; Zhang Z
Oncotarget; 2016 Dec; 7(50):83187-83199. PubMed ID: 27825122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
